Nicholas Argento
Endocrinology, Diabetes & Metabolism · Laurel, MDNPI 1093781155
Payments from drug & device makers
Across 1,602 payments — averaging $659.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dexcom, Inc.$386K
- Lilly USA, LLC$322K
- Novo Nordisk$146K
- Boehringer Ingelheim$48K
- Xeris Pharmaceuticals, Inc.$34K
- Tandem Diabetes Care, Inc.$28K
- plus $91K from 42 others
What the payments were for
- Consulting fees$60,4506%
- Speaking & faculty fees$875,84883%
- Travel & lodging$93,2769%
- Food & beverage$25,9882%
- Education$2480%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DEXCOM G7 GSS (161)$168,451
- DEXCOM G6 TRANSMITTER$152,856
- MOUNJARO$124,666
- JARDIANCE$104,648
- TRULICITY$102,730
- Ozempic$62,168
- RYBELSUS$57,628
- DEXCOM G6 CGM SYSTEM$45,768
- DEXCOM STELO GLUCOSE BIOSENSOR$43,462
- GVOKE PFS$30,570
- t:slim X2 Insulin Pump with Control-IQ$27,570
- AFREZZA$24,580
- Tresiba$16,357
- Omnipod$15,739
- INVOKANA$14,236
- DEXCOM CGM$13,040
- BAQSIMI$7,000
- AQUACEL AG$6,080
- GVOKE HYPOPEN$2,667
- SUR-FIT NATURA$1,600
How this compares
$1,055,809 in reported general payments places this provider in the 95th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.
See all endocrinology, diabetes & metabolism providers in Maryland →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 337 | $628,531 |
| JardianceEmpagliflozin | 368 | $499,303 |
| KorlymMifepristone | 11 | $474,965 |
| MounjaroTirzepatide | 145 | $265,664 |
| Tresiba Flextouch U-200Insulin Degludec | 125 | $186,987 |
| TrulicityDulaglutide | 87 | $142,996 |
| FarxigaDapagliflozin Propanediol | 106 | $129,277 |
| Tresiba Flextouch U-100Insulin Degludec | 141 | $105,765 |
| JanuviaSitagliptin Phosphate | 63 | $80,724 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 45 | $61,716 |
| AfrezzaInsulin Regular, Human | 15 | $60,858 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 28 | $49,298 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 30 | $48,957 |
| InvokanaCanagliflozin | 42 | $46,993 |
| RybelsusSemaglutide | 17 | $42,725 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog, Fiasp | $146,471 | $736,169435 claims |
| Boehringer IngelheimJardiance, Tradjenta | $47,792 | $508,946380 claims |
| Corcept TherapeuticsKorlym | $272 | $474,96511 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Lyumjev | $322,495 | $452,172309 claims |
| AstraZenecaFarxiga | $240 | $129,277106 claims |
| Mannkind CorporationAfrezza | $25,022 | $60,85815 claims |
| Johnson & JohnsonInvokana | $14,983 | $46,99342 claims |
| BayerKerendia | $304 | $42,02822 claims |
| AbbVieSynthroid | $291 | $19,097230 claims |
| Sanofi-aventis U.S. LLCAdmelog, Lantus | $755 | $13,67638 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $64 | $6,006489 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.
Other endocrinology, diabetes & metabolism in Laurel
- Jean ParkBaltimore$3.7M
- Michael DempseyRockville$2.7M
- Ilias SpanakisBaltimore$2.6M
- Helena RodbardRockville$2.4M
- Daniel GozziSuitland$1.2M
- Martin SarkarFrederick$1.1M
- Romeu AzevedoCamp Springs$1.1M
- Philip LevinBaltimore$702K
- David BrownRockville$497K
- Roberto SalvatoriBaltimore$403K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.